T. Rowe Price Investment Management, Inc. Centessa Pharmaceuticals PLC Transaction History
T. Rowe Price Investment Management, Inc.
- $162 Billion
- Q4 2024
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Centessa Pharmaceuticals PLC stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 3,418,600 shares of CNTA stock, worth $58.4 Million. This represents 0.04% of its overall portfolio holdings.
Number of Shares
3,418,600
Previous 3,556,023
3.86%
Holding current value
$58.4 Million
Previous $56.9 Million
0.71%
% of portfolio
0.04%
Previous 0.03%
Shares
3 transactions
Others Institutions Holding CNTA
# of Institutions
116Shares Held
123MCall Options Held
5.9KPut Options Held
97.2K-
Medicxi Ventures Management (Jersey) LTD20MShares$341 Million73.44% of portfolio
-
Index Venture Life Associates Vi LTD St. Helier, Y99.96MShares$170 Million99.89% of portfolio
-
General Atlantic LLC New York, NY9.68MShares$165 Million5.81% of portfolio
-
Perceptive Advisors LLC New York, NY6.35MShares$108 Million3.55% of portfolio
-
First Light Asset Management, LLC Edina, MN5.81MShares$99.1 Million9.51% of portfolio
About Centessa Pharmaceuticals plc
- Ticker CNTA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,339,296
- Market Cap $1.61B
- Description
- Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; an...